ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid-lowering therapies (LLT) are well-established in reducing cardiovascular complications and improving outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). However, the efficacy of LLT varies across different ethnic and geographical populations, necessitating further investigation.
objectivesTo evaluate the real-world efficacy and safety of the combination therapy of Ezetimibe 10 mg/Rosuvastatin 40 mg in Egyptian patients at very high risk of ASCVD.
methodsThis multicenter, prospective, single-arm, open-label study enrolled adult patients with documented ASCVD or at very high-risk profiles. Lipid parameters, including total cholesterol (TC), LDL-C, HDL-C, non-HDL-C, and triglycerides, were measured at baseline, 6 weeks, and 12 weeks. The primary endpoint was the proportion of patients achieving the ESC LDL-C target (< 55 mg/dL and ≥ 50% reduction). Safety assessments included adverse events, skeletal myopathy, hepatic enzyme alterations, and treatment discontinuation.
resultsA total of 1,854 participants from 25 centers across Egypt completed the 12-week follow-up. The mean age was 56 ± 11 years, with 68% male participants. Hypertension was prevalent in 72.7%, diabetes in 47.6%, smoking in 38.7%, prior ACS in 38.9%, previous percutaneous coronary intervention (PCI) in 43.7%, and prior CABG in 10.4% of the cohort. By week 12, TC decreased by 42.9%, LDL-C by 58.7%, and non-HDL-C by 54%, while HDL-C increased by 9.4%. LDL-C levels < 55 mg/dL were achieved in 35.5% of participants, ≥ 50% LDL-C reduction in 70.3%, and 32.2% met the combined ESC LDL-C goal. Skeletal muscle symptoms occurred in 11.4%, elevated liver enzymes in 4.9%, mostly mild in severity. Treatment discontinuation was minimal (1.9%), with most patients maintaining therapy.
conclusionIn Egyptian patients at very high risk of ASCVD, the combination of Ezetimibe 10 mg/Rosuvastatin 40 mg over 12 weeks demonstrated substantial LDL-C reduction and high attainment of ESC targets, with an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.